论文部分内容阅读
[目的]评价紫杉醇联合卡培他滨二线治疗晚期胃癌的疗效及安全性。[方法]经病理证实的进展期胃癌患者38例,紫杉醇160～175mg/m2静脉滴注3h,d1;联合卡培他滨1250mg/m2,口服,2次/d,d1～14,服用2周后休息1周;21d为1个周期。[结果]36例可评价疗效患者,PR9例,有效率为23.7%(95%CI:10.2%～37.2%)。中位TTP和OS分别为4.4(95%CI:3.4～5.4)个月和7.2(95%CI:6.6～12.1)个月。Ⅲ/Ⅳ度毒副反应主要为骨髓抑制、手足综合征及脱发。[结论]紫杉醇联合卡培他滨方案二线治疗晚期胃癌疗效确切,毒副作用小。
[Objective] To evaluate the efficacy and safety of second-line paclitaxel combined with capecitabine in the treatment of advanced gastric cancer. [Method] Thirty-eight patients with advanced gastric cancer confirmed by pathology were treated with paclitaxel 160 ~ 175mg / m2 intravenously for 3h and d1 with capecitabine 1250mg / m2 orally, 2 times / d and d1 ~ 14 for 2 weeks After a week off; 21d for a cycle. [Results] Among 36 evaluable patients, PR was 9 cases, with an effective rate of 23.7% (95% CI: 10.2% -37.2%). Median TTP and OS were 4.4 (95% CI: 3.4-5.4) months and 7.2 (95% CI: 6.6-12.1) months, respectively. Ⅲ / Ⅳ degree of toxicity mainly for myelosuppression, hand-foot syndrome and hair loss. [Conclusion] paclitaxel combined with capecitabine second-line treatment of advanced gastric cancer curative effect is exact, the side effects are small.